Skip to main content

CORRECTION article

Front. Oncol., 02 August 2022
Sec. Thoracic Oncology
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.980842

Corrigendum: Successful treatment of a patient with multiple-line relapsed extensive-stage small-cell lung cancer receiving penpulimab combined with anlotinib: A case report

This article is a correction to:

  1. Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report

    1. Read original article
Zibo Zhang&#x;Zibo Zhang†Yujun Li&#x;Yujun Li†Yan DongYan DongJia LiJia LiBin ZhangBin ZhangChunxia Zhang*Chunxia Zhang*Xiaonan Cui*Xiaonan Cui*
  • Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China

A Corrigendum on
Successful treatment of a patient with multiple-line relapsed extensive-stage small-cell lung cancer receiving penpulimab combined with anlotinib: A case report

by Zhang Z, Li Y, Dong Y, Li J, Zhang B, Zhang C and Cui X (2022) Front. Oncol. 12:846597. doi: 10.3389/fonc.2022.846597

In the published article, there was an error in the affiliations. Instead of including “Graduate School of Dalian Medical University, Dalian Medical University, Dalian, China”, all authors should be affiliated with “Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China” as above.

In the published article the order of the corresponding authors were incorrect. Instead of “Chunxia Zhang, qm1210@hotmail.com; Xiaonan Cui, cxn23@sina.com”, it should be “Xiaonan Cui cxn23@sina.com Chunxia Zhang qm1210@hotmail.com.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: penpulimab, anlotinib, ICI rechallenge, small-cell lung cancer, case report

Citation: Zhang Z, Li Y, Dong Y, Li J, Zhang B, Zhang C and Cui X (2022) Corrigendum: Successful treatment of a patient with multiple-line relapsed extensive-stage small-cell lung cancer receiving penpulimab combined with anlotinib: A case report. Front. Oncol. 12:980842. doi: 10.3389/fonc.2022.980842

Received: 29 June 2022; Accepted: 30 June 2022;
Published: 02 August 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Zhang, Li, Dong, Li, Zhang, Zhang and Cui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xiaonan Cui, cxn23@sina.com; Chunxia Zhang, qm1210@hotmail.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.